The Latest
-
Ned Pagliarulo/BioPharma Dive
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
-
Permission granted by Thermo Fisher Scientific
Sponsored by Thermo Fisher ScientificProcess intensification: Separating fact from fiction
Uncover four key misconceptions that could be holding your intensification strategies back — and how to set your initiatives up for success.
-
"Eli Lilly Corporate Center, Indianapolis, Indiana, USA" by Momoneymoproblemz is licensed under CC BY-SA 4.0
Gene editingEarly data for heart drug affirm Lilly’s billion-dollar bet on Verve
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
-
Getty Images
News roundupAstellas eyes more cost cuts; FDA panel to debate Moderna vaccine
The Japanese pharma is aiming for $1.3 billion in yearly savings between now and 2030. Elsewhere, Datroway gained a new clearance in breast cancer and the FDA approved a drug for hepatitis D.
-
Permission granted by Bristol Myers Squibb
Q&A // Brain drug revivalIn Alzheimer’s, Bristol Myers sees big promise beyond amyloid
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Kardigan, a startup run by former MyoKardia executives, outlined an offering that would support development of heart drugs licensed from Bristol Myers, Sanofi and Ionis Pharmaceuticals.
Updated 5 hours ago -
Scott Olson via Getty Images
Obesity drugsLilly’s triple-acting obesity drug hits goal in Phase 3 trial
Participants who stayed on the drug lost around one-quarter of their body weight, potentially setting a new benchmark for rivals like Novo Nordisk.
-
Getty Images
Parkinson’s drug from Biogen, Denali comes up short
High-level results have led the companies to scrap a mid-stage trial, though Denali plans to continue independently running a separate experiment focused on a certain subset of Parkinson’s patients.
Updated May 22, 2026 -
Michael M. Santiago via Getty Images
RA Capital banks $75M for a biotech SPAC
Research Alliance III follows a few months after Cormorant Asset Management priced a $150 million IPO for its own blank-check entity.
-
Permission granted by Bristol-Myers Squibb
Bristol Myers deepens AI investment with Anthropic deal
The collaboration marks an “evolution” in the pharmaceutical giant’s use of AI and adds to a series of broad deals its peers have used to adopt the technology across many day-to-day activities.
-
Permission granted by Parabilis
IPO windowAfter raising $800M, Parabilis seeks an IPO to pursue ‘undruggable’ targets
Parabilis is teeing up the latest high-profile stock issuance in a year when biotech IPOs are averaging more than $286 million in total proceeds.
-
Getty Images
BioMarin notches win in study that could expand use of top-selling medicine
The success came two days after a Phase 3 setback for another experimental drug and helps improve the position of Voxzogo amid increased competition.
-
Vadym Plysiuk via Getty Images
Startup launchesOorja, run by Acceleron veterans, launches to make new fibrosis drugs
The biotechnology startup emerged from stealth with a peptide drug it claims to have the potential to reverse lung scarring in people with idiopathic pulmonary fibrosis.
-
Scott Olson via Getty Images
Lilly snaps up Engage to advance non-viral genetic medicines
The acquisition is Lilly’s latest push into genetic medicine, giving it a technology designed to overcome some of the field’s longstanding limitations.
-
Getty Images
News roundup
Immunovant’s potential autoimmune ‘blockbuster’; Wave’s RNA editing update
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antitrust suit.
-
Spencer Platt via Getty Images
A migraine drugmaker heads to the public markets through reverse merger
Mentari Therapeutics, a spinout from the prolific hub-and-spoke biotech Paragon, is developing two medications it hopes can treat migraines that aren’t well controlled by existing drugs.
-
Adeline Kon/BioPharma Dive/BioPharma Dive
Deep Dive // Emerging biotechBiotech startups are built on venture capital. Track funding rounds here.
Two biotechs — radiopharmaceuticals specialist Full-Life Technologies and immune drugmaker Accro Bioscience — raised $160 million combined in a pair of equity financings announced Monday.
Updated 22 hours ago -
SpiffyJ via Getty Images
Relay drug shows early promise against rare blood vessel diseases
While early, the findings suggest the therapy could be superior to Novartis’ Vijoice at treating “vascular anomalies,” a cluster of chronic conditions with few available treatments.
-
Courtesy of Regeneron Pharmaceuticals
Regeneron immunotherapy combo comes up short in melanoma trial
A two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in market value.
-
Christopher Furlong via Getty Images
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
-
Getty Images
News roundup
Høeg fired in latest FDA shakeup; 20 people die after taking Amgen drug
The agency has once again shuffled the leadership for two top drug review offices. Elsewhere, Parabilis partnered with Regeneron and an obesity pill is headed toward an approval in China.
-
Getty Images
BioMarin drug acquired in buyout misses goal in rare disease study
Tested in a condition known as ENPP1 deficiency, the treatment failed a trial goal that’s important to regulators, spurring doubts about its approval prospects.
-
Getty Images
China competitionMerck ADC, licensed from China, hits mark in first big global trial
The endometrial cancer trial is the first of 17 late-stage studies Merck is running for a therapy that’s important to its ambitions of hitting $70 billion in annual sales next decade.
-
Permission granted by Stephanie Shiers, The University of Texas at Dallas
Deep Dive // Pain drugsA year after Vertex’s big launch, pain drug research faces a pivotal moment
Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
-
Getty Images
India’s pharma industry is going global. But can it catch up to China?
A record Sun Pharma acquisition signals global ambitions. But infrastructure, capital and policy gaps could stand in the way of India becoming an R&D powerhouse.
-
Sarah Silbiger via Getty Images
FDA hold puts Aardvark Prader-Willi drug in limbo
The company plans to unblind the late-stage study that was halted due to safety concerns, which could lead to an overhaul of its entire development program.
